With healthcare officials around the world ringing alarm bells over a weak global pipeline of antibiotics, Roche's pRED group is making good on its promised return to the field with a $560 million development deal, partnering up with a Phase II program underway at Polyphor.
Inova Diagnostics once again has its sights on rheumatoid arthritis-detecting technology, this week acquiring a novel platform developed at Hasselt University designed to identify autoantibody biomarkers for the debilitating condition.
In its joint venture, Glaxo will front $1.8 million for work on the thermostability of vaccines. GSK will set out to make adjuvants--used to boost the effectiveness of vaccines--more heat stable. The project fits within the broad scope of work attempting to break the "cold chain" supply process that requires vaccines to remain refrigerated--a big challenge for developing countries.
Pfizer announced in its quarterly statement today that Lilly had agreed to share the cost of development on tanezumab in exchange for a split of the profits. Lilly, which has come under increased scrutiny after a series of high-risk drug programs failed to pan out, will also pay an unspecified upfront--provided the FDA lifts a partial hold on the program.
Dutch CMO PharmaCell has inked a deal with the struggling Dendreon to manufacture its prostate cancer drug Provenge in Europe.
Swiss CRO Atheris Laboratories has signed a deal with Debiopharm to help develop a peptide cancer drug, optimizing leads for an innovative venom-derived treatment.
Allergan teamed up with the Dutch drug delivery company InnoCore this week to further develop sustained-release ophthalmic products using InnoCore's drug delivery platform SynBiosys.
Biotech Clovis Oncology is tapping Qiagen's diagnostic expertise as it develops an EGFR-targeting lung cancer treatment, tasking the German company with creating a companion test that can identify patients for clinical trials and, eventually, be sold alongside the drug.
AstraZeneca has partnered with the Wyss Institute to use its organs-on-chips technology--miniature human organs made of a clear, flexible polymer that contain tiny tubes lined with living human cells--to help improve the way it tests drugs for humans.
Terumo BCT, the blood-focused division of the Japanese med tech giant, has signed a deal with the U.S. Department of Defense to share costs in the development of a device that can treat donated blood used in emergency transfusions.